EUVIMEDEUVIMED entdecken
Crossref

Impact of Preoperative Osteosarcopenia and Postoperative Administration of Pancrelipase on the Prognosis of Borderline Resectable and Unresectable Locally Advanced Pancreatic Cancer

Michinori Matsumoto iD, Tadashi Uwagawa, Yoshihiro Shirai, Masashi Tsunematsu iD, Kenei Furukawa, Koichiro Haruki iD, Norimitsu Okui, Kohei Okazaki, Shunta Ishizaki, Toru Ikegami

The American Surgeon™ · 2025-01 · 91 (1) · 65-75

DOI: 10.1177/00031348241272420 ↗

Kurz gefasst

Fachartikel in der Zeitschrift The American Surgeon™, online erschienen am 07.08.2024. Verfasst von Michinori Matsumoto und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Surgery, The Jikei University School of Medicine, Minato-ku, Japan. Hauptthemen laut MEDLINE: Pancreatic Neoplasms, Sarcopenia. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 35 Literaturangaben. Gefördert von: Takeda Science Foundation, Japan Society for the Promotion of Science, Princess Takamatsu Cancer Research Fund.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

This study aimed to identify postoperative recurrence and prognostic factors, including osteosarcopenia for borderline resectable (BR) and unresectable locally advanced (UR-LA) pancreatic cancer and to examine the impact of postoperative pancreatic enzyme replacement therapy (PERT).

Methods

We retrospectively examined 32 resected patients with BR and UR-LA pancreatic cancer. We investigated independent factors in the disease-free survival and overall survival. The relation of osteosarcopenia with the clinicopathological factors was investigated. Additionally, the association of the administration of a standard dose of pancrelipase, the amount of lipase required for patients with pancreatic exocrine insufficiency, for ≥6 months postoperatively with improvement of sarcopenia, osteopenia, and osteosarcopenia and completion rate of adjuvant chemotherapy was investigated.

Results

Multivariate analyses identified osteosarcopenia ( P = 0.049) and lymph node metastasis ( P = 0.01) as independent recurrence predictors, and osteosarcopenia ( P = 0.002), maximum tumor diameter ≥40 mm ( P = 0.006), and no adjuvant therapy ( P = 0.01) as independent prognostic predictors. In the osteosarcopenia group, serum CA19-9 levels were higher ( P = 0.03). The administration of a standard dose of pancrelipase for ≥6 months postoperatively was none in the osteosarcopenia group (0% vs 42.9%, P = 0.01), while significantly improved postoperative sarcopenia (33% vs 0%, P = 0.004), increased number of cycles of adjuvant chemotherapy (n = 6 vs n = 3, P = 0.03), and the completion rate of adjuvant chemotherapy in excluding cases interrupted because of recurrence (86% vs 25%, P = 0.007).

Conclusions

Osteosarcopenia was an independent recurrent and prognostic factor in patients after pancreatectomy for locally advanced pancreatic cancer. Appropriate postoperative PERT may contribute to a better prognosis by improving sarcopenia and increasing the completion rate of adjuvant chemotherapy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Pancreatic NeoplasmsSarcopeniaHumansMaleFemaleRetrospective StudiesAgedMiddle AgedPrognosisLipaseNeoplasm Recurrence, LocalChemotherapy, AdjuvantPancreatectomyPostoperative CareAged, 80 and overDisease-Free Survival

Stichwörter der Autor:innen

osteosarcopeniapancreatic cancerpancreatic enzyme replacement therapypancreatic exocrine insufficiencypancrelipase

Substanzen

Lipase

Autor:innen und Institutionen

  • Department of Surgery, The Jikei University School of Medicine, Minato-ku, Japan.

ORCID-Profile: Michinori Matsumoto, Masashi Tsunematsu, Koichiro Haruki

Förderung

  • Takeda Science Foundation
  • Japan Society for the Promotion of Science
  • Princess Takamatsu Cancer Research Fund

Zitieren

APA

Matsumoto, M., Uwagawa, T., Shirai, Y., Tsunematsu, M., Furukawa, K., Haruki, K., Okui, N., Okazaki, K., Ishizaki, S., & Ikegami, T. (2025). Impact of Preoperative Osteosarcopenia and Postoperative Administration of Pancrelipase on the Prognosis of Borderline Resectable and Unresectable Locally Advanced Pancreatic Cancer. The American Surgeon™, 91(1), 65-75. https://doi.org/10.1177/00031348241272420

Vancouver

Matsumoto M, Uwagawa T, Shirai Y, Tsunematsu M, Furukawa K, Haruki K, et al. Impact of Preoperative Osteosarcopenia and Postoperative Administration of Pancrelipase on the Prognosis of Borderline Resectable and Unresectable Locally Advanced Pancreatic Cancer. The American Surgeon™. 2025;91(1):65-75. doi:10.1177/00031348241272420

BibTeX
@article{Matsumoto2025,
  author = {Matsumoto, Michinori and Uwagawa, Tadashi and Shirai, Yoshihiro and Tsunematsu, Masashi and Furukawa, Kenei and Haruki, Koichiro and Okui, Norimitsu and Okazaki, Kohei and Ishizaki, Shunta and Ikegami, Toru},
  title = {Impact of Preoperative Osteosarcopenia and Postoperative Administration of Pancrelipase on the Prognosis of Borderline Resectable and Unresectable Locally Advanced Pancreatic Cancer},
  journal = {The American Surgeon™},
  year = {2025},
  volume = {91},
  number = {1},
  pages = {65--75},
  doi = {10.1177/00031348241272420}
}
Kostenlos starten →